EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies

Jessica Garcia, Sean G Yates, Ravi Sarode, Guy Young, Ayesha Zia

Haemophilia · 2026-05 · 32 (3) · 834-839

DOI: 10.1111/hae.70258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 12.03.2026. Verfasst von Jessica Garcia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics Division of Hematology/Oncology UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Thrombin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half‐life FVIII (EHL‐FVIII) and non‐FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non‐factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can be utilized to evaluate hemostatic capacity.

Aim

To compare the endogenous thrombin potential (ETP) and peak thrombin (PT) in pediatric patients with moderate to severe haemophilia A (SHA) undergoing EHL‐FVIII therapies and EMI.

Methods

Platelet‐poor plasma (PPP) from PwHA on EHL‐FVIII or EMI prophylaxis was tested on the calibrated automated thrombogram (CAT) using PPP low reagent.

Results

ETP and PT were significantly higher in the EHL‐FVIII group compared to the EMI group.

Conclusion

Pediatric patients on EHL‐FVIII prophylaxis demonstrated higher ETP in vitro using PPP compared to those on EMI prophylaxis. These findings highlight the need for further systematic investigations to explore the implications of these differences in bleed control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIThrombinHumansChildHalf-LifeMaleChild, PreschoolAntibodies, BispecificAdolescentAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

FVIIIefanesoctocog alfaemicizumabhaemophiliathrombin generation

Substanzen

Factor VIIIThrombinemicizumabAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics Division of Hematology/Oncology UT Southwestern Medical Center, Dallas, Texas, USA.
  • Children's Health, Dallas, Texas, USA.
  • Department of Pathology UT Southwestern Medical Center, Dallas, Texas, USA.
  • Hemostasis and Thrombosis Center, Cancer and Blood Diseases Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.

Zitieren

APA

Garcia, J., Yates, S. G., Sarode, R., Young, G., & Zia, A. (2026). Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies. Haemophilia, 32(3), 834-839. https://doi.org/10.1111/hae.70258

Vancouver

Garcia J, Yates SG, Sarode R, Young G, Zia A. Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies. Haemophilia. 2026;32(3):834-839. doi:10.1111/hae.70258

BibTeX
@article{Garcia2026,
  author = {Garcia, Jessica and Yates, Sean G and Sarode, Ravi and Young, Guy and Zia, Ayesha},
  title = {Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {3},
  pages = {834--839},
  doi = {10.1111/hae.70258}
}
Kostenlos starten →